Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis, with a ...

OBJECTIVES: To evaluate the effect of minocycline as treatment for cutaneous calcinosis in limited cutaneous systemic sclerosis (lcSSc). METHODS: Patients with lcSSc who had cutaneous calcinosis ...

Low doses of glucocorticoids added to immunosuppression yield no significant benefit for skin fibrosis in early diffuse ...

Health charity Scleroderma & Raynaud's UK (SRUK) is urging the public to take a 60-second online test to find out if they may ...

Scleroderma is more likely to cause serious complications if it affects your ability to breathe or process food. It can be fatal. Systemic sclerosis has three subtypes – diffuse, limited and sine ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase III drugs for Systemic Sclerosis (Scleroderma) ...

3 with diffuse systemic sclerosis, 1 with limited systemic sclerosis, 1 with overlap syndrome and 1 with Sjögren’s syndrome. Results: Although the vascular alterations in collagen diseases were ...

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of menopausal hormone therapy, according to data published in Rheumatology.

41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...

Diagnoses were made according to the 2013 ACR/EULAR SSc criteria (29) and subtypes were ascertained as diffuse or limited. The control group comprised 80 eyes of 40 ... The studied groups differed in ...